Capricor Therapeutics is a leading biotechnology company focused on developing new treatments for diseases. On May 15, 2026, Roth Capital analyst Boobalan Pachaiyappan lowered the price target for Capricor Therapeutics to $38.00. This new target still represents a potential 27.47% upside from the stock's price of $29.81 at the time. The analyst's valuation comes as Capricor Therapeutics awaits a key decision. Its main therapy candidate, deramiocel, a promising Duchenne muscular dystrophy treatment, is under ...